Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

VOLUNTARY ANNOUNCEMENT

BUSINESS PARTNER IDEAYA RECEIVED FDA CLEARANCE OF IND APPLICATION FOR IDE034

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**") is pleased to announce that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA) ("**IDEAYA**"), a company dedicated to the research and development of precision treatment drugs for tumors, has received the clearance of an investigational new drug ("**IND**") application with the U.S. Food and Drug Administration ("**FDA**") for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate ("**ADC**"). IDEAYA expects to begin patient enrollment in the first quarter of 2026, initially evaluating solid tumors known to co-express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers.

IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by the Company and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting the Company's technical capabilities in bispecific ADC discovery and development.

The IND clearance for IDE034 is a significant milestone for IDEAYA in advancing its first-in-class TOP1 ADC pipeline toward a bispecific, precision-targeted therapeutic strategy, which also marks a key achievement in the Company's externally licensed project. It also validates our RenLite® platform and proprietary linker-payload technologies that enable the discovery and optimization of bispecific ADCs. We look forward to seeing IDE034 demonstrate clinical potential across multiple B7H3/PTK7 co-expressing solid tumors, offering new therapeutic options for patients.

Preclinical studies have shown that IDE034 monotherapy induces deep and durable tumor regressions in multiple B7H3/PTK7-positive tumor models, demonstrating strong anti-tumor activity. In addition, IDEAYA plans to explore combination strategies with its PARG inhibitor IDE161 to enhance the durability of response and intends to present additional preclinical data supporting the combination rationale of PARG and TOP1 ADC at a major medical conference in the first half of 2026. B7H3 and PTK7 are co-expressed in lung, colorectal, and head and neck cancers at approximately 30%, 46% and 27%, respectively, indicating the broad clinical potential of IDE034.

Looking ahead, the Company will continue to provide high-quality source antibodies through Project Integrum to support the clinical translation of licensed projects and actively explore additional early-stage assets for external licensing opportunities.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, December 5, 2025

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive director, Dr. Ni Jian and Dr. Zhang Haichao as executive directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive directors.